Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients

Günter Stein1,, Sybille Franke1, Arezki Mahiout2, Sabine Schneider3, Heide Sperschneider1, Sabine Borst4 and Jörg Vienken4

1 Department of Internal Medicine IV, Friedrich Schiller University of Jena, Germany, 2 Institute of Cell and Protein Engineering, Medical Park Hannover, Germany, 3 Kuratorium für Dialyse und Nierentransplantation, Jena, Germany and 4 Fresenius Medical Care, Bad Homburg, Germany



   Abstract
 Top
 Abstract
 Introduction
 Subjects and methods
 Pentosidine measurement by HPLC
 AGE peptide and AGE-ß2...
 Results
 Discussion
 References
 
Backround. The accumulation of advanced glycation end-products (AGEs) in end-stage renal disease (ESRD) influenced by dialysis modalities is of current interest. Highly permeable membranes in haemodialysis or haemofiltration should be able to eliminate circulating AGEs as well as their AGE precursors more efficiently.

Methods. In our study, 10 non-diabetic and 10 diabetic ESRD patients were on haemodialysis with low-flux membranes (LF) followed by a cross-over haemodialysis with high-flux or super-flux polysulfone membranes (HF, SF) for 6 months each. We measured the protein-bound pentosidine and free pentosidine serum levels by high-performance liquid chromatography (HPLC) as well as the serum AGE peptide, AGE-ß2-microglobulin and ß2-microglobulin concentrations, using ELISA assays.

Results. All parameters investigated were significantly higher in dialysis patients than in healthy subjects. The reduction rates during a single dialysis session were found to be higher using the SF than those obtained with the HF (free pentosidine 82.4±7.3 vs 76.6± 8.7%; AGE peptides 79.7±7.7 vs 62.3±14.7%; AGE-ß2-microglobulin 64.0±16.5 vs 45.4±17.7%; ß2-microglobulin 70.5±5.6 vs 58.2±6.0%). The protein-bound pentosidine levels remained constant over the respective dialysis sessions. In the 6-month treatment period with the SF, decreased pre-dialysis serum levels of protein-bound pentosidine, free pentosidine and AGE peptides were observed in non-diabetics and diabetics as compared with values obtained with the LF. The respective pre-dialysis AGE-ß2-microglobulin concentrations decreased insignificantly, whereas those of ß2-microglobulin were significantly lower. Using the HF dialyser, only moderate changes of the parameters measured were noted.

Conclusion. Treatment with the biocompatible polysulfone SF dialyser seems to be better suited to lower serum AGE levels and to eliminate their precursors.

Keywords: advanced glycation end-products; haemodialysis; high-flux polysulfone



   Introduction
 Top
 Abstract
 Introduction
 Subjects and methods
 Pentosidine measurement by HPLC
 AGE peptide and AGE-ß2...
 Results
 Discussion
 References
 
Advanced glycation end-products (AGEs) are formed during the Maillard reaction by the non-enzymatic glycation and oxidation of proteins constituting a heterogeneous class of structures. AGE modification of proteins leads to tissue damage through an alteration of tissue protein structure and function, and stimulates cellular responses mediated by specific receptors (e.g. RAGE). Whether AGEs accumulated in vivo are implicated in the process of aging as well as in the pathogenesis of several diseases, including diabetes, atherosclerosis and Alzheimer's disease, is still a matter of debate [17].

In renal failure, the increased oxidative stress enhances the formation of AGE precursors along with an impaired clearance and may cause their accumulation. These processes may further result in the generation and accumulation of AGEs.

Serum AGEs circulate in the form of modified proteins or peptides and, as in the case of pentosidine, also in its free form. Using immunological determination or fluorescence detection methods, serum AGE levels have been reported to be increased in diabetic as well as in non-diabetic patients with end-stage renal failure (ESRD) [811].

We investigated the influence of maintenance haemodialysis treatment on a subset of serum AGE levels (AGE peptides <30 kDa, AGE-modified ß2-microglobulin, pentosidine) using high-flux or super-flux biocompatible polysulfone membranes in a cross over study comprising 20 ESRD patients. This study aimed to find out whether AGE-modified proteins or peptides could be effectively removed through internal filtration combined with increased convectional forces and whether highly permeable membranes in haemodialysis or haemodiafiltration could be a new therapeutic approach in treating ESRD.



   Subjects and methods
 Top
 Abstract
 Introduction
 Subjects and methods
 Pentosidine measurement by HPLC
 AGE peptide and AGE-ß2...
 Results
 Discussion
 References
 
In this study, we investigated 10 non-diabetic and 10 diabetic patients who had been on maintenance haemodialysis (Table 1Go). Before commencing the study, all patients were dialysed using low-flux membranes (polycarbonate or un-modified cellulose (LF)) for at least more than 1 month followed by a dialysis with high-flux, biocompatible polysulfone membranes (Super-flux F800S (SF) and High-flux F60S (HF), Fresenius Medical Care, Germany) over a period of 6 months each. The study design is shown in Figure 1Go. In this cross over study, dialysis treatment of non-diabetic patients started with the HF followed by the SF, whereas diabetics started with the SF and changed over to the HF after 6 months. The membrane's ultrafiltration coefficients were as follows: LF membranes: <5 ml/hxmmHg, HF: 40 ml/hxmmHg, SF: >60 ml/hxmmHg. SF membranes are characterized by both a higher UF-coefficient and a higher permeability for larger solutes. A reduction of the inner diameter of these capillary membranes down to 165 µm enhances convective transport. The ß2-microglobulin and albumin sieving coefficients were 65%/0.1% for the HF and 90%/1% for the SF, respectively. The cut-offs range from 30 to 40 kDa for the HF and from 40 to 50 kDa for the SF.


View this table:
[in this window]
[in a new window]
 
Table 1. Demographic parameters of subjects examined in this study

 


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1. Study design.

 
All patients had been on stable heparin anticoagulation and erythropoetin (Epo) therapies with a diuresis of <500 ml/d. Dialysis was performed three times a week for 4–5.5 h (blood flow: 250 ml/min, dialysate flow: 500 ml/min, bicarbonate buffer, substitution volume: 1.8 l/h).

Pre- and post-dialysis serum samples were obtained at the start and the end of dialysis sessions.

As controls, serum samples of age-matched healthy subjects were used.

Serum protein concentration was determined according to the Biuret method and serum albumin by colorimetric end-point measurement using routine autoanalyser methods.



   Pentosidine measurement by HPLC
 Top
 Abstract
 Introduction
 Subjects and methods
 Pentosidine measurement by HPLC
 AGE peptide and AGE-ß2...
 Results
 Discussion
 References
 
Pentosidine measurement was performed using the HPLC assay described by Miyata et al. [11,12]. For quantitation of total pentosidine concentrations, 50 µl of serum (containing approximately 4 mg of proteins) were hydrolysed by 50 µl 6 N HCl at 110°C under nitrogen atmosphere for 16 h, subsequently neutralized with 100 µl of 5 N NaOH and 200 µl of 0.5 M phosphate buffer (pH 7.4), filtered through a 0.45 µm-Millipore filter, and diluted 20-fold with phosphate-buffered saline (PBS). For determination of free pentosidine levels, 50 µl of serum were diluted with 150 µl of distilled water followed by protein precipitation with 200 µl of 10% trichloroacetic acid, the protein-free centrifuged supernatants were filtered through a 0.45 µm-Millipore filter. Pentosidine in these specimens was analysed by reverse-phase HPLC with gradient separation on a RP-18 column (Merck, Germany) under fluorescence detection (excitation-emission wavelength: 335/385 nm). Synthetic pentosidine was used to obtain a standard curve (kindly provided by Dr T. Miyata, Tokai University, Japan).

Protein-bound pentosidine (expressed in pmol per mg protein) was calculated as follows:

[Total serum pentosidine (pmol/ml)-Free serum pentosidine (pmol/ml)] / Serum protein concentration (mg/ml)



   AGE peptide and AGE-ß2-microglobulin measurement by competitive ELISA
 Top
 Abstract
 Introduction
 Subjects and methods
 Pentosidine measurement by HPLC
 AGE peptide and AGE-ß2...
 Results
 Discussion
 References
 
In-vitro preparation of AGE-modified proteins
The preparation of AGE-BSA as well as of AGE-ß2-microglobulin was performed as described by Nakayama et al. [13]. Carboxymethyllysine-BSA (CML-BSA) was prepared as described by Ikeda et al. [14].

AGE-KLH: Keyhole limpet haemocyanin (KLH, 2 mg/ml, Sigma, Germany) was incubated with PBS (pH 7.4) containing 1 M glucose (Sigma, Germany) at 37°C in the dark under aerobic and aseptic conditions for 6 weeks. After incubation, unbound glucose was removed by gel filtration using PBS as an elution solvent. The extent of lysine-modified residues of KLH reacting with glucose determined according to the method described by Habeeb [15] was found to be 83%.

Immunological techniques
Polyclonal anti-AGE antibody: Polyclonal AGE antibodies were obtained by immunizing New Zealand rabbits receiving a primary immunization (500 µg of AGE-KLH at two sites of the back) with Freund's complete adjuvant. Booster injections with Freund's incomplete adjuvant (250 µg) were given each month over a 3-month period. After immunization controlled by Ouchterlony double diffusion, both antisera yielded a titre of 1:2500 dilution. The polyclonal antibodies were purified by affinity chromatography, using protein A (Affi-Gel, Pierce, USA) in the first and AGE-collagen (AminoLink Plus Immobilization Kit, Pierce, USA) in the second step.

The major immunological epitope of the antibody has been found to be a CML-protein adduct (70%), following the method described by Ikeda [14]. Thirty per cent of the antigens recognized by the antibody were identified as non-CML adducts. The anti-AGE antibody did not react with early Amadori products, pentosidine or caproyl pyrraline as well as with glycated proteins incubated under antioxidative conditions.

Monoclonal anti-AGE antibody: The production of the monoclonal anti-AGE antibody has been performed as described by Niwa et al. [16]. Six-week-old female BALB/c mice were given intraperitoneal injections of AGE-KLH (0.1 mg, four times at 2-week intervals) prepared as described with Freund's adjuvant. The culture of the antibody-secreting fused cells has been performed according to Köhler [17]. Thus, the antibody-secreting cells were injected into 8-week-old female BALB/c mice. The ascitic fluid was collected after 2 weeks, and the IgG fraction was purified using DEAE-cellulose column chromatography (Amersham Pharmacia Biotech, Germany).

The subclass of the antibody was determined as IgG2a{kappa} and tested for its identity with the monoclonal AGE-antibody produced by T. Niwa (kindly provided by Dr T. Niwa, Nagoya University Daiko Medical Center, Japan). Using a competitive assay, it could be shown that the antibody exclusively recognized the proteins glycated under aerobic conditions. The antibody did not react with glycated proteins incubated under antioxidative condition. Furthermore, the anti-AGE antibody was unreactive to early Amadori products, pentosidine and caproyl pyrraline. CML-BSA significantly inhibited the recognition of AGE-BSA by the antibody, suggesting that CML was the major existing antigenic determinant.

AGE peptides
Sample preparation: pre- and post-dialysis serum samples were diluted 10-fold with PBS solution and filtered through 30-kDa-membrane filter units (Millipore, USA).

The AGE peptide levels in the filtrates were measured using the polyclonal rabbit anti-AGE antibody. The wells (96-well MaxiSorp ELISA plate, Nunc, Denmark) were coated at 4°C with AGE-BSA (1 µg AGE-BSA in 100 µl of 50 mM carbonate buffer per well, pH 9.6) overnight, washed with phosphate-buffered saline containing 0.5% Tween-20 (pH 7.4) and blocked at room temperature with 200 µl of 0.5% gelatine in 50 mM carbonate buffer for 1 h. After washing, 50 µl-aliquots of samples or standards and 50 µl-aliquots of the anti-AGE antibody (500 ng/ml) were added to each well and incubated at room temperature for 1 h, then washed and subsequently incubated with 100 µl of alkaline phosphatase-conjugated mouse anti-rabbit IgG (1 h, room temperature, Biorad, USA). The plates were washed again and developed with 100 µl of alkaline phosphatase substrate (Biorad, USA). The absorbance at 405 nm was measured by a microplate reader after a 30-min reaction time. The effect of polyclonal anti-AGE antibody on AGE-BSA was used as a standard. Results were expressed in UI per ml (1 UI/ml represents the amount of AGE contained in the samples, which is equivalent to the inhibition of the AGE antibody binding to the antigen).

AGE-ß2-microglobulin
Sample preparation: pre- and post-dialysis serum samples were diluted 10-fold with PBS solution and filtered through 30-kDa-membrane filter units (Millipore, USA). The ß2-microglobulin fractions of the filtrates were isolated by affinity chromatography using a polyclonal anti-ß2-microglobulin antibody (DAKO, Denmark). The AGE-ß2-microglobulin levels were measured directly in the ß2-microglobulin fractions.

After activating the carboxy-terminal portion of AGE-ß2-microglobulin (10 µg/ml) with 0.1 M EDAC/NHS (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccininmide; Sigma, Germany) at a ratio of 1:1 at room temperature for 30 min, the activated protein was diluted with 1 M carbonate buffer (pH 8.6), and 100 µl per well were used to coat the plate (Covalink-NH ELISA plates, Nunc, Denmark) at 4°C for 30 min. The plates were washed four times with distilled water followed once with a PBS-rinse containing 0.5% Tween-20. The reaction was blocked at room temperature with 200 µl of 0.5% gelatine in PBS-Tween (pH 7.4) for 1 h. After washing the plates three times with PBS-Tween, 50 µl of test samples and 50 µl of monoclonal mouse anti-AGE antibody (100 ng/ml) were added to each well and incubated at room temperature for 1 h, washed, followed by incubation with 100 µl of alkaline phosphatase-conjugated anti-mouse IgG (1 h at room temperature; Biorad, USA). The plates were washed and developed with 100 µl of alkaline phosphatase substrate. The absorbance at 405 nm was measured by a microplate reader after a 30-min reaction time. The results were expressed in UI per ml. An average of 0.5 µg/ml AGE-ß2-microglobulin inhibited about 50% of the antibody binding to the antigen.

ß2-Microglobulin
ß2-Microglobulin levels in pre- and post-dialysis serum samples were measured nephelometrically using a latex-enhanced ß2-microglobulin kit (BNII Kit, The Binding Site, UK).

Calculations and statistics
Data are expressed as means±SD. To exclude the influence of haemoconcentration, all post-dialysis serum concentrations measured were corrected according to the method described by Bergstrom and Wehle [18]. Statistics were performed using the Wilcoxon test for comparison of paired samples, the Mann–Whitney U test for comparison of unpaired samples and the Pearson correlation test for estimating relationships between variables. Statistical significance was achieved when the P-value was <0.05.



   Results
 Top
 Abstract
 Introduction
 Subjects and methods
 Pentosidine measurement by HPLC
 AGE peptide and AGE-ß2...
 Results
 Discussion
 References
 
Pentosidine
The protein-bound serum pentosidine levels determined in dialysis patients were over 10-fold higher than in healthy subjects (1.7±0.5 pmol/mg, n=60). The initial pre-dialysis values obtained during dialysis with LF membranes were not significantly different in the non-diabetic and the diabetic patient group (23.5±7.2 vs 27.1±12.4 pmol/mg). Moreover, these pentosidine levels remained constant over the respective dialysis sessions (e.g. SF dialyser pre- and post-dialysis levels measured in months 11 and 12: 16.2±4.5 vs 17.2±4.0 pmol/mg) indicating that the protein-bound pentosidine was not filtered through the dialysis membranes.

As shown in Figure 2Go, a moderate decrease in protein-bound serum pentosidine levels was observed, being less than 15% in non-diabetic patients using the HF dialyser (months 1–6). In contrast, in the following period of dialysis with the SF (months 7–12) these levels decreased significantly in months 8, 9 and 10 as compared with values obtained with the LF membranes. Likewise, in the diabetic patient group, treatment with the SF (months 1–6) was associated with significant decreases in months 1 and 2, followed by persistently lower values in the HF-phase afterwards. In both groups, SF dialysis caused a reduction of protein-bound pentosidine levels by nearly 30%.



View larger version (50K):
[in this window]
[in a new window]
 
Fig. 2. Protein-bound pentosidine pre-dialysis serum levels in non-diabetic and diabetic patients under haemodialysis treatment using low-flux (LF) and SF, HF (F800S, F60S) membranes (*P<0.05 vs low-flux values).

 
Free pentosidine was not detectable in the serum of normal subjects. Initial pre-dialysis values of dialysis patients were similar in the non-diabetic and the diabetic group (85.8±24.3 and 80.7±32.9 pmol/ml, respectively). Free pentosidine was cleared during dialysis by all membranes used (e.g. pre- and post-dialysis LF values of the non-diabetic patient group: 85.8±24.3 and 20.5±13.0 pmol/ml, respectively). The reduction rate of free pentosidine was found to be significantly higher using the SF as compared with the HF (82.4±7.3 vs 76.6±8.7%). During dialysis with the SF membrane, the free pentosidine pre-dialysis levels were significantly lower in months 7–10 for the non-diabetic and in months 1–5 for the diabetic patient group, respectively, as compared with the LF-values (Figure 3Go). There were no significant changes during the period of HF dialyser application.



View larger version (48K):
[in this window]
[in a new window]
 
Fig. 3. Free pentosidine predialysis serum levels in non-diabetic and diabetic patients under haemodialysis treatment using low-flux (LF) and SF, HF (F800S, F60S) membranes (*P<0.05 vs low-flux values).

 
Moreover, pre-dialysis free pentosidine levels correlated significantly with those of protein-bound pentosidine in the non-diabetic and the diabetic patient group in each month (P<0.05) as well as during the whole study period (r=0.76, P<0.0001).

AGE peptides
All AGE peptide levels measured in this study were significantly higher than those in healthy subjects (1.1±0.3 UI/ml, n=20).

Contrary to pentosidine, the initial pre-dialysis AGE-peptide values were significantly lower in the non-diabetic than in the diabetic group (41.1±18.9 vs 61.5±19.0 UI/ml; P=0.01). AGE peptides were cleared by all membranes used in the study (e.g. pre- and post-dialysis SF values of the diabetic patient group in month 6: 41.5±9.0 and 8.9±4.2 UI/ml, respectively); the SF was characterized by a significantly higher reduction rate than the HF (79.7±7.7 vs 62.3±14.7%).

During dialysis with the SF membrane, the pre-dialysis AGE peptide serum levels decreased significantly in the non-diabetic patient group (months 9–12) as compared with the month-7-value as well as in the diabetic patient group (months 2–6) as compared with the LF-value (Figure 4Go). No significant changes could be observed during the HF dialyser period of application in both patient groups.



View larger version (47K):
[in this window]
[in a new window]
 
Fig. 4. AGE peptide predialysis serum levels in non-diabetic and diabetic patients under haemodialysis treatment using low-flux (LF) and SF, HF (F800S, F60S) membranes (non-diabetics: *P<0.05 vs month-7 value; diabetics: P<0.05 vs LF value).

 

AGE-ß2-microglobulin
AGE-ß2-microglobulin was not detectable in healthy subjects. In dialysis patients, the initial pre-dialysis levels were insignificantly lower in non-diabetics than in diabetics (1.72±1.08 vs 2.93±1.9 UI/ml, n.s.). In both patient groups, a 6-month treatment with the SF dialyser was associated with decreases in the pre- and post-dialysis concentrations (Figure 5Go). The AGE-ß2-microglobulin reduction rate induced by the SF was found to be significantly higher than that of the HF (64.0±16.5 vs 45.4±17.7%).



View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5. AGE ß2-microglobulin pre-dialysis serum levels in non-diabetic and diabetic patients under haemodialysis treatment using low-flux (LF) and SF, HF (F800S, F60S) membranes.

 

ß2-Microglobulin
All ß2-microglobulin levels determined in dialysis patients were significantly elevated as compared with healthy subjects (1.17±0.4 µg/ml, n=26).

The initial pre-dialysis ß2-microglobulin levels in the non-diabetic and the diabetic patient group were nearly identical (55.0±7.9 vs 48.0±19.0 µg/ml). A significant reduction could be obtained at the end of dialysis session when the HF or SF membranes were used (e.g. pre- and post-dialysis SF values of the diabetic patient group in month 1: 31.0±8.1 and 9.7±4.2 µg/ml, respectively). The SF was characterized by a significantly higher reduction rate for ß2-microglobulin than the HF dialyser (70.5±5.6 vs 58.2±6.0%). During the application period of both, the HF and SF dialyser, the ß2-microglobulin pre-dialysis levels decreased significantly in the non-diabetic as well as in the diabetic patient group as compared with the LF-values (Figure 6Go).



View larger version (45K):
[in this window]
[in a new window]
 
Fig. 6. ß2-Microglobulin pre-dialysis serum levels in non-diabetic and diabetic patients under haemodialysis treatment using low-flux (LF) and SF, HF (F800S, F60S) membranes (*P<0.05 vs LF values).

 

Albumin
The serum albumin concentrations did not change significantly during dialysis using all three membranes. In the 12-month study period, the pre-dialysis mean values ranged from 43.1 to 40.6 g/l in the non-diabetic and from 43.6 to 38.0 g/l in the diabetic patient group, respectively.



   Discussion
 Top
 Abstract
 Introduction
 Subjects and methods
 Pentosidine measurement by HPLC
 AGE peptide and AGE-ß2...
 Results
 Discussion
 References
 
Renal failure is characterized by increased levels of circulating AGEs [19,20]. Up to now, such structurally identified epitopes, like pentosidine, carboxymethyllysine, pyrraline and imidazolone have been assessed using different methods [2125]. But the clinical significance of all these results is still lacking.

Nonetheless, as in the case of dialysis-related amyloidosis, several groups are looking for strategies to decrease the amount of accumulated ß2-microglobulin as well as AGE products and to lower the risk of AGE generation per se [26]. As reported recently, circulating pentosidine and carboxymethyllysine levels are influenced by membrane characteristics [27,28]. The free form of pentosidine (molecular weight 379 Da) is totally excreted via the glomerulus in patients with normal renal function. Its accumulation is the result of a decreased glomerular filtration rate. More than 95% of the circulating pentosidine is linked to serum proteins, i.e. almost exclusively to albumin (>95%) and cannot be eliminated by standard haemodialysis [12]. The pre-dialysis total pentosidine levels were found to be lower in HD patients dialysed with high-flux polysulfone membranes than those treated with classical cellulose membranes [29].

In our study, we have investigated whether a new biocompatible polysulfone membrane, the so-called Superflux F800S (SF) (Fresenius Medical Care, Germany) enabling increased convectional forces and internal filtration through a modified geometry of the fibre and increased permeability, is able to remove significant amounts of AGEs in comparison with another high-flux membrane (HF) (F60S, Fresenius Medical Care, Germany) and with non-biocompatible, low-flux membranes consisting of polycarbonate or cellulose, respectively.

Our results demonstrate that in dialysis patients serum protein-bound pentosidine levels, representing their albumin-linked form, can be lowered by means of polysulfone HF membranes, with the highest reduction obtained using the SF. The similarity of the pre- and post-dialysis levels suggests that pentosidine was not cleared by all the membranes used in this study. As cited elsewhere, it may be possible that the formation of pentosidine-modified proteins is lower when using biocompatible polysulfone membranes, especially the SF dialyser [28]. On the other hand, the SF is characterized by the highest reduction rate of free pentosidine, of AGE peptides with a molecular weight <30 kDa and of AGE-ß2-microglobulin as compared with the HF and LF dialysers. Moreover, free pentosidine levels correlate closely with those of protein-bound pentosidine. These observations may indicate possible links between the removal of low-molecular-weight AGEs during dialysis and the decreased protein-bound pentosidine levels resulting from treatment with biocompatible membranes. This is supported by our finding that the pre-dialysis levels of free pentosidine and AGE peptides decreased significantly in the period of dialysis with the SF dialyser, suggesting a higher removal rather than the formation of new AGE products. Furthermore, the high reduction rate of free pentosidine and AGE peptides may reflect that not only these AGE structures but also other low-molecular-weight AGEs as well as reactive carbonyl compounds, as a source of protein modification, are more efficiently eliminated by the SF than by the other membranes.

Interestingly, contrary to the pre-dialysis protein-bound pentosidine and free pentosidine levels, AGE peptide concentrations were significantly higher in the diabetic group. This difference may indicate a possible influence of hyperglycaemia on the generation of CML-modified peptides. This is supported by the findings of Henle, who found the pre-dialysis plasma concentrations of the Amadori product fructoselysine, a major precursor of CML, significantly higher in diabetic than in non-diabetic patients [30].

In agreement with recent data, the AGE-ß2-microglobulin and ß2-microglobulin have been effectively removed by the HF membranes in each dialysis session for both patient groups studied, with an advantage of the SF [31].

To the best of our knowledge, no data on serum AGE-ß2-microglobulin and serum ß2-microglobulin levels in haemodialysis patients measured simultaneously have been reported yet. Treatment with both polysulfone HF membranes was associated with lower pre- and post-dialysis ß2-microglobulin levels. For AGE-ß2-microglobulin, such changes could only be observed in the application period of the SF dialyser.

In conclusion, treatment with the SF dialyser seems to be advantageous for the removal of free pentosidine, AGE-modified low-molecular-weight proteins and peptides. This observation indicates that this biocompatible polysulfone membrane may be superior to LF membranes.



   Acknowledgments
 
Parts of this study were presented in abstract form at the 31st and the 32nd Annual Meeting of the American Society of Nephrology, Philadelphia 1998 and Miami 1999. The authors thank Drs K. Kurokawa and T. Miyata for their support and for giving the opportunity to learn the pentosidine determination method at their laboratory.



   Notes
 
Correspondence and offprint requests to: Prof. Dr G. Stein, Department of Internal Medicine IV, Erlanger Allee 101, D-07740 Jena, Germany. Back



   References
 Top
 Abstract
 Introduction
 Subjects and methods
 Pentosidine measurement by HPLC
 AGE peptide and AGE-ß2...
 Results
 Discussion
 References
 

  1. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic and clinical implications for diabetes and aging. Lab Invest1994; 70: 138–151[ISI][Medline]
  2. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med1995; 46: 223–234[ISI][Medline]
  3. Vlassara H. Protein glycation in the kidney: role in diabetes and aging. Kidney Int1996; 49: 1795–1804[ISI][Medline]
  4. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med1996; 28: 419–426[ISI][Medline]
  5. Colaco CALS, Ledesma MD, Harrington CR, Avila J. The role of the Maillard reaction in other pathologies: Alzheimer's disease. Nephrol Dial Transplant1996; 11 [Suppl. 5]: 7–12[ISI][Medline]
  6. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol1998; 44: 1013–1023[ISI]
  7. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of ‘carbonyl stress’ in long-term uremic complications. Kidney Int1999; 55: 389–399[ISI][Medline]
  8. Dolhofer-Bliesener R, Lechner B, Deppisch R et al. Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant1995; 10: 657–664[Abstract]
  9. Yanagisawa K, Makita Z, Shiroshita K et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism1998; 47: 1348–1353[ISI][Medline]
  10. Friedlander MA, Wu YC, Elgawish A, Monnier VM. Early and advanced glycosylation end products. Kinetics of formation and clearence in peritoneal dialysis. J Clin Invest1996; 97: 728–735[Abstract/Free Full Text]
  11. Miyata T, Ueda Y, Shinzato T et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol1996; 7: 1198–1206[Abstract]
  12. Miyata T, Ueda Y, Yoshida A et al. Clearence of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int1997; 51: 880–887[ISI][Medline]
  13. Nakayama H, Taneda S, Kuwajima S et al. Production and characterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun1989; 162: 740–745[ISI][Medline]
  14. Ikeda K, Higashi T, Sano H et al. N{varepsilon}-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry1996; 35: 8075–8083[ISI][Medline]
  15. Habeeb AF. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem1966; 14: 328–326[ISI][Medline]
  16. Niwa T, Miyasaki S, Katsuzaki T et al. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int1995; 48: 771–778[ISI][Medline]
  17. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature1975; 256: 495–497[ISI][Medline]
  18. Bergstrom J, Wehle B. No change in corrected ß2-microglobulin concentration after cuprophane haemodialysis. Lancet1987; 1(8533): 628–629[Medline]
  19. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med1991; 325: 836–842[Abstract]
  20. Makita Z, Bucala R, Rayfield EJ et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet1994; 343: 1519–1522[ISI][Medline]
  21. Friedlander MA, Wu YC, Schulak JA, Monnier VM, Hricik DE. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis1995; 25: 445–451[ISI][Medline]
  22. Degenhardt TP, Grass L, Reddy S et al. The serum concentration of advanced glycation end-product N{varepsilon} (carboxymethyl) lysine is increased in uremia. Kidney Int1997; 52: 1064–1067[ISI][Medline]
  23. Portero-Otin M, Pamplona R, Bellmunt MJ, Bergua M, Prat J. Glycaemic control and in vivo non-oxidative Maillard reaction: urinary excretion of pyrraline in diabetes patients. Eur J Clin Invest.1997; 27: 767–773[ISI][Medline]
  24. Monnier VM, Nagaraj RH, Portero-Otin M et al. Structure of advanced Maillard reaction products and their pathological role. Nephrol Dial Transplant1996; 11 (Suppl. 5): 20–26[ISI][Medline]
  25. Niwa T, Katsuzaki T, Miyazaki S et al. Amyloid ß2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int1997; 51: 187–194[ISI][Medline]
  26. Van Ypersele de Strihou C. Are biocompatible membranes superior for hemodialysis therapy? Kidney Int1997; 52 [Suppl. 62]: 101–104
  27. Weiss MF. Pathogenic role of advanced glycation end-products (AGEs): an overview. Perit Dial Int1999; 19 [Suppl. 2]: 47–52
  28. Jadoul M, Ueda Y, Yasuda Y et al. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of ‘carbonyl stress’. Nephrol Dial Transplant1999; 55: 2487–2492
  29. Stein G, Franke S, Sperschneider H et al. Decrease in serum pentosidine levels of ESRD patients during polysulfone hemodialysis. Nephrol Dial Transplant1999; 14: 1607–1608
  30. Henle T, Deppisch R, Beck W, Hergesell O, Hänsch GM, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant1999; 14: 1968–1975[Abstract/Free Full Text]
  31. Stein G, Günther K, Sperschneider H et al. Clinical evaluation of a new dialyzer, FLX-12 GW, with polyester-polymer alloy membrane. Artif Organs1993; 17: 339–345[ISI][Medline]
Received for publication: 4. 5.00
Revision received 21.11.00.